Efficacy of Perioperative Chemotherapy for Resectable Pancreatic Adenocarcinoma: A Phase 2 Randomized Clinical Trial

Abstract

Importance: Clinical outcomes after curative treatment of resectable pancreatic ductal adenocarcinoma (PDA) remain suboptimal. To assess the potential of early control of systemic disease with multiagent perioperative chemotherapy, we conducted a prospective trial.

Objective: To determine 2-year overall survival (OS) using perioperative chemotherapy for resectable PDA.

Design, setting, and participants: This was a randomized phase 2 trial of perioperative chemotherapy with a pick-the-winner design. It was conducted across the National Clinical Trials Network, including academic and community centers all across the US. Eligibility required patients with Zubrod Performance Score of 0 or 1, confirmed tissue diagnosis of PDA, and resectable disease per Intergroup criteria.

Interventions: Perioperative (12 weeks preoperative, 12 weeks postoperative) chemotherapy with either fluorouracil, irinotecan, and oxaliplatin (mFOLFIRINOX, arm 1) or gemcitabine/nab-paclitaxel (arm 2).

Main outcomes and measures: The primary outcome was 2-year overall survival (OS), using a pick-the-winner design; for 100 eligible patients, accrual up to 150 patients was planned to account for cases deemed ineligible at central radiology review.

Results: From 2015 to 2018, 147 patients were enrolled; 43 patients (29%) had ineligible disease, beyond resectability criteria, at central radiology review. There were 102 eligible and evaluable patients, 55 in arm 1 and 47 in arm 2, of whom the median (range) age was 66 (44-76) and 64 (46-76) years, respectively; 36 patients (65%) in arm 1 and 24 (51%) in arm 2 were men. In arm 1, 34 (62%) had Zubrod Performance Score of 0, while in arm 2, 31 (66%) did; and 44 (80%) in arm 1 and 39 (83%) in arm 2 had head tumors. Of 102 patients, 84% and 85% completed preoperative chemotherapy, 73% and 70% underwent resection, and 49% and 40% completed all treatment. Adverse events were expected hematologic toxic effects, fatigue, and gastrointestinal toxicities. Two-year OS was 47% (95% CI, 31%-61%) for arm 1 and 48% (95% CI, 31%-63%) for arm 2; median OS was 23.2 months (95% CI, 17.6-45.9 months) and 23.6 months (95% CI, 17.8-31.7 months). Neither arm's 2-year OS estimate was significantly higher than the a priori threshold of 40%. Median disease-free survival after resection was 10.9 months in arm 1 and 14.2 months in arm 2.

Conclusions and relevance: This phase 2 randomized clinical trial did not demonstrate an improved OS with perioperative chemotherapy, compared with historical data from adjuvant trials in resectable pancreatic cancer. Two-year OS was 47% with mFOLFIRINOX and 48% with gemcitabine/nab-paclitaxel for all eligible patients starting treatment for resectable PDA. The trial also demonstrated adequate safety and high resectability rates with perioperative chemotherapy, and challenges in quality control for resectability criteria.

Trial registration: ClinicalTrials.gov Identifier: NCT02562716.

Conflict of interest statement

Conflict of Interest Disclosures: Dr Sohal reported personal fees from Perthera, Incyte, and Ability Pharma. Dr Beg reported personal fees from AstraZeneca, Merck, Array, and Ipsen during the conduct of the study. Dr Chiorean reported personal fees from Celgene during the conduct of the study; and personal fees from Array, Ipsen, Legend, and Sobi, and grants from Boehringer Ingelheim, Halozyme, Merck, Stemline, Roche, MacroGenics, Fibrogen, Rafael, and Clovis outside the submitted work. Dr Lowy reported personal fees from HUYA, Merck, and Rafael, and grants from Tanabe Mitsubishi and Syros outside the submitted work. Dr Philip reported personal fees from Celgene honoraria outside the submitted work. No other disclosures were reported.

Figures

Figure 1.. CONSORT Flow Diagram

Intraop indicates intraoperative; mFOLFIRINOX, modified FOLFIRINOX, treatment with fluorouracil, irinotecan, and oxaliplatin; postop, postoperative; preop, preoperative.

Figure 2.. Overall Survival

mFOLFIRINOX indicates modified FOLFIRINOX, treatment with fluorouracil, irinotecan, and oxaliplatin.